<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>nivolumab &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/nivolumab/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 09 Jan 2026 16:40:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>nivolumab &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>GRIm Score Predicts Nivolumab Efficacy in Melanoma</title>
		<link>https://bioengineer.org/grim-score-predicts-nivolumab-efficacy-in-melanoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 09 Jan 2026 16:39:47 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Immunotherapy Response** **Açıklama:** 1. **GRIm Score:** Çalışmanın temel konusu ve anahtar biyobelirteci. 2. **Nivolumab:** Araştırmanın odaklandığı spesifik immünoterapi ilacı. 3.]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **GRIm Score]]></category>
		<category><![CDATA[Malignant Melanoma]]></category>
		<category><![CDATA[nivolumab]]></category>
		<category><![CDATA[Predictive Biomarker]]></category>
		<guid isPermaLink="false">https://bioengineer.org/grim-score-predicts-nivolumab-efficacy-in-melanoma/</guid>

					<description><![CDATA[In the realm of oncology, the quest to improve patient outcomes in advanced malignant melanoma is both critical and complex. Recent research conducted by Oksuz et al. introduces a groundbreaking perspective on how the GRIm score can serve as a predictive biomarker for the response to nivolumab therapy, a cornerstone in the treatment of this [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">315362</post-id>	</item>
		<item>
		<title>NADIM ADJUVANT Trial Highlights Advantages of Chemo-Immunotherapy After Surgery in Stage IB–IIIA NSCLC</title>
		<link>https://bioengineer.org/nadim-adjuvant-trial-highlights-advantages-of-chemo-immunotherapy-after-surgery-in-stage-ib-iiia-nsclc/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 08 Sep 2025 09:14:26 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[chemo-immunotherapy]]></category>
		<category><![CDATA[minimal residual disease (MRD)]]></category>
		<category><![CDATA[NADIM ADJUVANT trial]]></category>
		<category><![CDATA[nivolumab]]></category>
		<category><![CDATA[non-small cell lung cancer (NSCLC)]]></category>
		<guid isPermaLink="false">https://bioengineer.org/nadim-adjuvant-trial-highlights-advantages-of-chemo-immunotherapy-after-surgery-in-stage-ib-iiia-nsclc/</guid>

					<description><![CDATA[Interim findings from the NADIM ADJUVANT Phase III clinical trial conducted by the Spanish Lung Cancer Group (GECP) have unveiled promising evidence that adjuvant chemo-immunotherapy can significantly reduce the risk of disease recurrence in patients diagnosed with completely resected stage IB to IIIA non-small cell lung cancer (NSCLC). These results, which were presented at the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">267462</post-id>	</item>
		<item>
		<title>Chemo-Immunotherapy Exhibits Promising Efficacy in Advanced HPV-Negative Head and Neck Cancer Patients</title>
		<link>https://bioengineer.org/chemo-immunotherapy-exhibits-promising-efficacy-in-advanced-hpv-negative-head-and-neck-cancer-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 06 Mar 2025 21:31:35 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[chemo-immunotherapy]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[HPV-negative head and neck cancer]]></category>
		<category><![CDATA[nivolumab]]></category>
		<category><![CDATA[PD-L1 biomarker]]></category>
		<guid isPermaLink="false">https://bioengineer.org/chemo-immunotherapy-exhibits-promising-efficacy-in-advanced-hpv-negative-head-and-neck-cancer-patients/</guid>

					<description><![CDATA[Researchers at the University of Chicago Medicine Comprehensive Cancer Center are redefining the therapeutic landscape for advanced head and neck cancers. Their findings, published in JAMA Oncology, showcase a groundbreaking treatment regimen that integrates immunotherapy with traditional chemotherapy, yielding substantial tumor shrinkage in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC). The study [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">237802</post-id>	</item>
	</channel>
</rss>
